Structural biology in drug design: selective protein kinase inhibitors
- 1 May 2002
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 7 (11) , 601-611
- https://doi.org/10.1016/s1359-6446(02)02290-0
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- From Consensus Sequence Peptide to High Affinity Ligand, a “Library Scan” StrategyJournal of Biological Chemistry, 2001
- Protein kinase inhibitors: emerging pharmacophores 1997 - 2000Expert Opinion on Therapeutic Patents, 2001
- Inhibitors of the JNK signaling pathwayDrugs of the Future, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- The cell cycle and drug discovery: the promise and the hopeDrug Discovery Today, 1999
- Src homology-2 domains: Structure, mechanisms, and drug discoveryBiopolymers, 1998
- Structure-Based Design of a Novel Series of Nonpeptide Ligands That Bind to the pp60src SH2 DomainJournal of the American Chemical Society, 1997
- Crystal structure of the Cys2 activator-binding domain of protein kinase Cδ in complex with phorbol esterPublished by Elsevier ,1995
- Growth factor signaling by receptor tyrosine kinasesNeuron, 1992
- THE PROTEIN KINASE C FAMILY: HETEROGENEITY AND ITS IMPLICATIONSAnnual Review of Biochemistry, 1989